ORIC

Oric Pharmaceuticals, Inc.

7 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 4

Raised $59.9 million through ATM offerings in Q1 2026.

capital raise

70%

bearishMay 4

Net loss widened to $35.8 million for the quarter.

earnings miss

60%

bearishMay 4

R&D expenses increased 28% year-over-year to $31.4 million.

margin compression

50%

bullishMay 4

Raised $59.9 million through ATM offerings in Q1 2026.

capital raise

70%

bearishMay 4

Net loss widened to $35.8 million for the quarter.

earnings miss

60%

bearishMay 4

R&D expenses increased 28% year-over-year to $31.4 million.

margin compression

50%

bullishMay 4

Raised $59.9 million through ATM offerings in Q1 2026.

capital raise

70%

bearishMay 4

Net loss widened to $35.8 million for the quarter.

earnings miss

60%

bearishMay 4

R&D expenses increased 28% year-over-year to $31.4 million.

margin compression

50%

bullishMay 4

Raised $59.9 million through ATM offerings in Q1 2026.

capital raise

70%

bearishMay 4

Net loss widened to $35.8 million for the quarter.

earnings miss

60%

bearishMay 4

R&D expenses increased 28% year-over-year to $31.4 million.

margin compression

50%

bullishMay 4

Raised $59.9 million through ATM offerings in Q1 2026.

capital raise

70%

bearishMay 4

Net loss widened to $35.8 million for the quarter.

earnings miss

60%

bearishMay 4

R&D expenses increased 28% year-over-year to $31.4 million.

margin compression

50%

bullishMay 4

Raised $59.9 million through ATM offerings in Q1 2026.

capital raise

70%

bearishMay 4

Net loss widened to $35.8 million for the quarter.

earnings miss

60%

bearishMay 4

R&D expenses increased 28% year-over-year to $31.4 million.

margin compression

50%

bullishMay 4

Raised $59.9 million through ATM offerings in Q1 2026.

capital raise

70%

bearishMay 4

Net loss widened to $35.8 million for the quarter.

earnings miss

60%

bearishMay 4

R&D expenses increased 28% year-over-year to $31.4 million.

margin compression

50%

Filing History

10-QMay 4, 2026

The Q1 2026 filing highlights a company at a critical inflection point. ORIC has successfully de-risked its early-stage pipeline by prioritizing its most promising assets and securing the capital necessary to enter pivotal trials. The move to a Phase 3-ready profile is a significant value-inflection event that shifts the investment thesis from speculative discovery to clinical execution. However, the ultimate success of the company depends on its ability to translate Phase 1b signals into statistically significant Phase 3 outcomes while managing a high burn rate. Investors must weigh the impressive early efficacy and safety data against the reality of a crowded competitive field and the immense capital requirements of global registrational trials. The next 12 to 18 months will be decisive as the Himalayas-1 trial progresses and enozertinib data matures.